Last reviewed · How we verify
Oravue (IOPRONIC ACID)
Oravue (generic name: IOPRONIC ACID) is a iopronic acid drug. It is currently in Phase 2 development.
Oravue works by binding to and modulating the activity of a specific protein or receptor in the body.
Oravue, also known as iopronic acid, is a small molecule drug of unknown target and class. Its commercial status and approved indications are currently unknown. As a small molecule, Oravue is likely to work by interacting with specific biological molecules to produce its therapeutic effect. Further information on its pharmacokinetics, safety, and efficacy is needed to fully understand its clinical utility. Its development and ownership history are also unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IOPRONIC ACID |
|---|---|
| Drug class | iopronic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Think of it like a key fitting into a lock. Oravue is the key that binds to a specific lock, or protein, in the body, which helps to turn off or on certain cellular processes that are involved in the disease it's meant to treat. This binding action helps to restore balance to the body's normal functioning.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oravue CI brief — competitive landscape report
- Oravue updates RSS · CI watch RSS
Frequently asked questions about Oravue
What is Oravue?
How does Oravue work?
What is the generic name of Oravue?
What drug class is Oravue in?
What development phase is Oravue in?
Related
- Drug class: All iopronic acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing